KURA - Kura Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
17.26
+0.54 (+3.23%)
At close: 4:00PM EDT

17.26 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close16.72
Open16.68
Bid17.27 x 800
Ask17.74 x 1300
Day's Range16.51 - 17.46
52 Week Range6.35 - 21.42
Volume643,554
Avg. Volume673,509
Market Cap964.863M
Beta (5Y Monthly)2.28
PE Ratio (TTM)N/A
EPS (TTM)-1.56
Earnings DateMay 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.38
  • GlobeNewswire

    Kura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced updated clinical outcome data from its RUN-HN study, a Phase 2 open-label, single-arm trial of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) whose disease had progressed after prior therapy. A copy of the presentation is available on Kura's website at www.kuraoncology.com/pipeline/publications.

  • GlobeNewswire

    Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that three abstracts highlighting its drug candidate tipifarnib have been accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) Virtual Scientific Program, to be held May 29-31, 2020. “We are pleased to announce the presentation of three clinical abstracts for tipifarnib, including an oral presentation highlighting single-agent activity in multiple solid tumors with HRAS mutations,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

  • Thomson Reuters StreetEvents

    Edited Transcript of KURA earnings conference call or presentation 4-May-20 8:30pm GMT

    Q1 2020 Kura Oncology Inc Earnings Call

  • GlobeNewswire

    Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

    SAN DIEGO, May 08, 2020 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.

  • GlobeNewswire

    Kura Oncology to Present at BofA Securities Virtual Health Care Conference 2020

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the BofA Securities Virtual Healthcare Conference 2020. Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.

  • GlobeNewswire

    Kura Oncology Announces Pricing of $125 Million Public Offering of Common Stock

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 9,100,000 shares of its common stock at a price to the public of $13.75 per share. The gross proceeds to Kura from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Kura, are expected to be approximately $125.1 million. The offering is expected to close on or about May 8, 2020, subject to customary closing conditions.

  • GlobeNewswire

    Kura Oncology Announces Commencement of Public Offering of Common Stock

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the offering, Kura expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. SVB Leerink, Cowen and Credit Suisse are acting as joint bookrunning managers in the offering.

  • Kura Oncology, Inc. (KURA) Q1 2020 Earnings Call Transcript
    Motley Fool

    Kura Oncology, Inc. (KURA) Q1 2020 Earnings Call Transcript

    Joining me on the call from Kura are Dr. Troy Wilson, our President and Chief Executive Officer and Dr. Marc Grasso, our Chief Financial Officer and Chief Business Officer. Jim Basta, our Chief Legal Officer; Kirsten Flowers, our Chief Commercial Officer; Kathy Ford, our Chief Operating Officer; and Dr. Bridget Martell, our acting Chief Medical Officer are also with us and available to answer questions. Before I turn the call over to Dr. Wilson, I would like to remind you that today's call will include forward-looking statements based on current expectations.

  • GlobeNewswire

    Kura Oncology Reports First Quarter 2020 Financial Results

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2020 financial results and provided a corporate update. “We recently completed a strategic review of our portfolio with the goal of prioritizing programs that have the highest potential to create value,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

  • GlobeNewswire

    Kura Oncology to Report First Quarter 2020 Financial Results

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report first quarter 2020 financial results after the close of U.S. financial markets on Monday, May 4, 2020. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 877-516-3514 for domestic callers and 281-973-6129 for international callers and entering the conference code: 2085246.

  • Why Kura Oncology Is Skyrocketing Today
    Motley Fool

    Why Kura Oncology Is Skyrocketing Today

    Shares of Kura Oncology (NASDAQ: KURA) -- a clinical-stage biopharmaceutical company that focuses on developing cancer treatments -- were up by 42.6% as of 1:49 p.m. EDT on Tuesday. The company did not report any news, but its stock is probably riding the wave of Syndax Pharmaceuticals (NASDAQ: SNDX), another clinical-stage drugmaker whose shares are up by more than 50% as a result of positive data from a phase 1 clinical trial. Syndax released data from a phase 1 clinical trial for SNDX-5613 on Monday, saying that the data provided "the first clinical evidence that disrupting the interaction between menin and MLL1 with our potent and selective inhibitor, SNDX-5613, can induce response in patients with genetically defined acute leukemias."

  • Thomson Reuters StreetEvents

    Edited Transcript of KURA earnings conference call or presentation 25-Feb-20 9:30pm GMT

    Q4 2019 Kura Oncology Inc Earnings Call

  • GlobeNewswire

    Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead drug candidate, tipifarnib, for the treatment of adult patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma (FTCL) and nodal peripheral T-cell lymphoma with T follicular helper (TFH) phenotype. “This important designation from the FDA comes just two months after tipifarnib was awarded Fast Track for the treatment of patients with HRAS mutant head and neck squamous cell carcinomas (HNSCC),” said Bridget Martell, M.A., M.D., Acting Chief Medical Officer of Kura Oncology.

  • GlobeNewswire

    Kura Oncology Reports Fourth Quarter and Full Year 2019 Financial Results

    – Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas anticipated to complete enrollment in first quarter of 2021 – – Company.

  • GlobeNewswire

    Kura Oncology to Participate in Three Upcoming Investor Conferences

    SAN DIEGO, Feb. 19, 2020 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.

  • GlobeNewswire

    Kura Oncology to Report Fourth Quarter and Full Year 2019 Financial Results

    SAN DIEGO, Feb. 18, 2020 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.

  • Benzinga

    The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 23) Baudax Bio Inc (NASDAQ: BXRX ) Mesoblast limited (NASDAQ: ...

  • GlobeNewswire

    Kura Oncology Announces Transition of Chief Medical Officer

    – Dr. Antonio Gualberto to step down after enabling multiple registrational strategies for tipifarnib, positioning program for success – – Clinical development, regulatory and.

  • 3 Healthcare Stocks That Can Double in the Next Year
    TipRanks

    3 Healthcare Stocks That Can Double in the Next Year

    Risk and reward are two of the most commonly used words in investing. The two are symbiotic and complement each other perfectly. Where there is more risk, the reward is likely to be more abundant. Of course, the equation works the other way too: less risk, probably less reward.The thesis is simple: a company such as Google is likely a pretty safe place for an investment. But with a market cap of $1 trillion, how much value can the company add to its share price? On the other hand, investing in a fledgling biotech with life-changing treatments in the pipeline could potentially see an investment yield extraordinary returns. Let’s not forget, though, this sort of investment also carries a significant amount of risk with it.With this in mind, TipRanks’ Stock Screener pointed us in the direction of three Healthcare stocks the experts on the Street think could soar in the year ahead. And by soar, we mean at least double their current value. The risk here as an investor is higher, but as we know by now, so are the possible rewards. As an added bonus, all three currently have a Strong Buy consensus rating from the Street. Let’s take a look at the data.ProQR Therapeutics (PRQR)ProQR’s back story is unusual. The company was founded after CEO Daniel de Boer’s newborn son was diagnosed with cystic fibrosis. De Boer, with the help of several co-founders, then formed ProQR – a biotech with a focus on providing new medicines for rare diseases. There are approximately 7,000 rare diseases in the world today, and only 400 currently have treatments, a situation ProQR hopes to change with the use of RNA therapies.The company has a diverse portfolio of therapies all in different stages of development. Among these are Sepofarsen, a treatment for Leber congenital amaurosis (LCA-10), the most common genetic cause of childhood blindness. Sepofarsen works by repairing the genetic defect in the RNA, with it standing to fill a gap as there aren’t any approved treatments available. The FDA and EMA have granted the drug orphan designation, and top-line data from the on-going Phase 2/3 Illuminate trial is expected during the first half of 2021. The company is also developing QR-421a, a treatment for Usher syndrome, a rare genetic disease that is the main cause for combined blindness and deafness. It should be noted that the therapy has been granted fast track designation by the FDA.Evercore’s Joshua Schimmer is impressed with Sepofarsen’s results so far. The 5-star analyst explained, “We saw 12 month data help confirm the durability of treatment effect in the pivotal Phase 2/3 dose through 12 months. The strong responses were maintained across visual acuity, mobility and sensitivity endpoints. The Phase 1/2 results bode well for the Phase 2/3 and may help validate the other pipeline opportunities… We remain encouraged by the LCA10 12-month data and see read-through to other larger indications.”Therefore, Schimmer reiterated an Outperform rating on PRQR, along with a price target of $34. Should the target be met, investors stand to pocket a massive 323% 12-month gain. (To watch Schimmer’s track record, click here)The Street is equally confident in the rare disease fighter’s ability to soar over the next 12 months. A Strong Buy analyst consensus is formed of Buy ratings only, 5 to be precise. The average price target is $28.80 and indicates possible upside of 258%. (See ProQR stock analysis on TipRanks) Cellectis SA (CLLS)French gene-editing pioneer Cellectis has been turning heads recently with its novel approach to cancer treatment.The company has developed a gene-editing technology called TALEN and has been making deals with fellow companies to advance effective cancer therapies. It recently announced a deal with Iovance Biotherapeutics, to which Cellectis has granted exclusive global rights for the use of its gene-editing technology to edit a series of cancer treatments known as tumor-infiltrating lymphocytes, or TILs. Cellectis, in return, will receive royalties on sales of gene-edited TILs from Iovance along with development and sales milestone payments.Cellectis also has deals with French pharmaceutical company Servier. The two are collaborating on five targets, including UCART19, a cellular therapy candidate against lymphoid malignancies progressing through trials. Additionally, Cellectis has a partnership with cancer-focused biotech Allogene. The company has been granted a license from Cellectis for the development of ALLO-501, a similar treatment to UCART19 but manufactured using a different process. Phase 1 has started in relapsed/refractory non-Hodgkin lymphoma.Nomura’s Christopher Marai believes Cellectis remains “grossly undervalued vs. peers.” The 4-star analyst noted, “We estimate that even a modest 8x on $80 million in potential royalties (estimate 8% royalties on sales, and up to $185 million in milestones per target) is justified by ALLO’s valuation (that incorporates mostly ALLO-501, in our view). This suggests that UCART19 alone should be worth $640 million in enterprise value to CLLS, or $15/share alone. This does not consider the 69.1% stake in Calyxt (~$125 million enterprise value).”What does this mean, then? It means Marai is bullish on CLLS. The analyst reiterated a Buy rating on Cellectis alongside a price target of $73. Should the figure be met, gains of 300% could be in the cards over the next year. (To watch Marai’s track record, click here)And what does the rest of the Street reckon 2020 has in store for the gene-editing company? Upside is the answer – Cellectis’ Strong Buy consensus rating breaks down into 4 Buys and 1 Hold. The average price target is $42.75 and implies a possible 12-month rise of 134%. (See Cellectis stock analysis on TipRanks) Kura Oncology (KURA)Kura is another biotech fighting the good fight against cancer. The company is focused on treatments for solid tumors and blood cancers, with several candidates in the pipeline.All eyes, though, are currently on the company’s lead candidate, Tipifarnib, an oral nonpeptidomimetic farnesyl transferase inhibitor. It can be used in both solid tumors and hematologic malignancies such as acute myeloid leukemia. The drug is presently in various stages of development for the treatment of several indications, and was recently granted fast track designation by the FDA for the treatment of patients with HRAS-mutant head and neck squamous cell carcinoma (HNSCC).Last month, Kura presented data from its ongoing Phase 2 trial for tipifarnib in peripheral T-cell lymphoma (PTCL) at the American Society of Hematology (ASH). Deutsche Bank’s Konstantinos Aprilakis came away impressed. The analyst stated, “We see the impressive clinical efficacy presented for tipifarnib in AITL at ASH as well as the positive regulatory guidance, especially the low bars for success in the pivotal trial, as encouraging for the company and supportive of an accelerated path forward for tipifarnib in the setting of blood cancers.”To this end, Aprilakis left a Buy rating and price target of $28 unchanged, implying upside potential of a handsome 119%. (To watch Aprilakis’ track record, click here)Other members of the Street are with the Deutsche analyst on Kura. 4 Buy recommendations from analysts tracked over the last three months add up to a Strong Buy consensus rating. The average price target comes in at $29.50 and indicates potential upside of 131%. (See Kura stock analysis on TipRanks)

  • GlobeNewswire

    Kura Oncology to Present at J.P. Morgan Healthcare Conference

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced its participation at the 38th Annual J.P. Morgan Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Thursday, January 16, 2020 at 10:00 a.m. PT / 1:00 p.m. ET, followed by a Q&A session at 10:30 a.m. PT / 1:30 p.m. ET. Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.

  • GlobeNewswire

    Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Kirsten Flowers as Chief Commercial Officer. Ms. Flowers joins Kura most recently from Array Biopharma, where she served as head of commercial operations until the completion of its $11.4 billion acquisition by Pfizer in July 2019. “Kirsten is a world-class leader in building successful commercial organizations and launching precision medicines for the treatment of cancer,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

  • GlobeNewswire

    Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead drug candidate, tipifarnib, for the treatment of patients with HRAS mutant head and neck squamous cell carcinomas (HNSCC) after progression on platinum therapy. “We are very encouraged by our growing body of clinical data for tipifarnib in HRAS mutant HNSCC and believe that the FDA’s Fast Track designation puts us one step closer to delivering a precision medicine treatment for patients with this devastating disease,” said Antonio Gualberto, M.D., Ph.D., Head of Development and Chief Medical Officer of Kura Oncology.

  • Kura Oncology, Inc. (KURA): Hedge Funds Can’t Make Up Their Minds
    Insider Monkey

    Kura Oncology, Inc. (KURA): Hedge Funds Can’t Make Up Their Minds

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

  • GlobeNewswire

    Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma

    – Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma – – Enhanced activity (40% CR rate, 70% ORR).

  • GlobeNewswire

    Kura Oncology to Participate in Piper Jaffray Healthcare Conference

    SAN DIEGO, Nov. 26, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.